However, previous clinical trials evaluating the influence of recombinant human interleukin-2 (rhuIL-2) as adjuvant to chemotherapy in adult patients with pulmonary TB showed inconsistent results [16–33]. The gene discussed is IL2; the disease is pulmonary tuberculosis.